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Local ablative techniques have been developed to enable local control of unresectable tumors. Ablation
has been performed with several modalities including ethanol ablation, laser ablation, cryoablation, and
radiofrequency ablation. Microwave technology is a new thermal ablation technique for different types of
tumors, providing all the beneﬁts of radiofrequency and substantial advantages. Microwave ablation has
been applied to liver, lung, kidney and more rarely to bone, pancreas and adrenal glands.
Preliminary works show that microwave ablation may be a viable alternative to other ablation tech-
niques in selected patients. However further studies are necessary to conﬁrm short- and long-term
effectiveness of the methods and to compare it with other ablative techniques, especially RF.
 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
In recent years there has been a growing interest in ablative
therapies for the treatment of unresectable tumors in various
organs.
Local ablative techniques have been developed to enable local
control of tumors and cytoreduction, above all for primitive liver
tumors, without damage of the healthy parenchyma.1 Tumor
ablation is deﬁned as the direct application of chemical or thermal
energy to a tumor to obtain cellular necrosis.2 Ablation has been
performed with several modalities including ethanol ablation, laser
ablation, cryoablation, and radiofrequency ablation.
Radiofrequency ablation remains the most widely used ablative
technique worldwide.3
Microwave technology is a new thermal ablation technique for
different types of tumors, providing all the beneﬁts of radio-
frequency and substantial advantages.2 Preliminary works show
that microwave ablation may be a viable alternative to other
ablation techniques in selected patients.
2. Principles of microwave ablation
Microwave radiation lies between infrared radiation and radi-
owaves with frequencies from 900 to 2450 MHz. Heating of theciates Ltd. Published by Elsevier Lttissue is based on agitation of water molecules inducing cellular
death via coagulation necrosis; electrical charge on the water
molecule ﬂips back and forth 2–5 billion times a second depending
on the frequency of the microwave energy.2
Microwave ablation offers many of the beneﬁts of others abla-
tion techniques, in particular RF, and has several other advantages
including: higher intratumoral temperatures, larger tumor ablation
volumes, faster ablation times, ability to use simultaneously
multiple applicators,4 optimal heating of cystic masses and tumors
close to the vessels, and less procedural pain.2,4–7 Due to this last
reason microwave ablation can be proposed also in outsetting
patients.
Radiofrequency ablation causes cellular death via thermocoa-
gulation necrosis; heat is generated by ions oscillation and collision
proportionally to intensity of radiofrequency current. Alternatively,
microwave produces an electromagnetic wave around insulated,
electrically independent antenna; electromagnetic wave produces
the agitation of polar water molecules within surrounding tissue8;
heat is generated by molecules friction.
With RF ablation, the zone of active tissue heating is limited to
a few millimetres surrounding the active electrode, with the
remainder of the ablation zone being heated via thermal conduc-
tion.2 Thanks to a better convection proﬁle, microwave energy
produces a larger zone of active heating (up to 2 cm surrounding the
antenna) thus allowing more uniform cells kill in the target area.9
RF ablation is also limited by the increase in impedance with
tissue boiling and charring, because water vaporization and chard. All rights reserved.
Fig. 1. Microwave ablation system (Evident TM Microwave ablation System/Covidien Ltd): antenna (a); microwave generator (b).
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microwaves, ablations do not seem to be subject to this limitation.
As other ablation techniques, microwave ablation allows for
different approaches, including percutaneous, laparoscopic, and
open surgical access. Percutaneous approach can be performed
with Ultrasound (US) or Computerized Tomography (CT) guide,
according to the site of the lesion and the preference of operator. In
our experience, when the procedure is performed in angiographic
suite on the angiographic bed, the US-guide positioning of the
antenna can be aided using C-arm cone-beam CT, a new tool ofFig. 2. Microwave ablation of a colorectal metastasis. Pre-procedural US (a). The procedure
beam CT (d); antenna inside the lesions is well visible (arrows). CT performed 1 months afangiographic systems, to conﬁrm correct position of the needle
inside the tumor.
Contrast enhanced US (CUES) can be useful to identify hyper-
vascular lesions and to conﬁrm complete ablation after the
procedure.
Laparoscopic and open surgical approaches are used only to
ablate lesions not reachable percutaneously or in patients eligible
for other abdominal interventions in the same time.
Anyway ablation is performed using a thin (14.5-gauge)
antenna that is attached, with a coaxial cable, to the microwavewas performed with laroscopic approach during colon resection (b-c) and C-arm cone-
ter the procedure with calculation of ablation volume.
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915 MHz.
In literature different protocols of time and power of ablation
have been proposed according to the tissue and antenna type.
Recently, Hope et al. published an experimental study about renal
microwave ablation recommending the application of 45 W for
10 min.10
Electromagnetic microwave is emitted from the exposed, non-
insulated portion of the antenna.
Due to the properties of microwave ablation does not require
the placement of grounding pads.2
After clinical introduction, several years ago, microwave energy
has not beenwidely applied because ablated areas produced by the
original technology were too small.
Then, advances in the engineering of microwave, in term of
material and structure, have overcome size and time limitations,
thanks to optimized electromagnetic power deposition into
a tissue.
To our knowledge, there is currently only one microwave abla-
tion system (Evident TM Microwave ablation System/Covidien Ltd)
(Fig. 1) globally available.
Different shape of antenna (straight or loop) has been
proposed.7,11 At the moment straight morphology is the only
available.
The ablation of large tumors can be time consuming to ensure
total overlapping coverage of ablation zones; thus the use of
multiple electrodes to achieve large coagulation volumes has been
proposed.8 Microwave should bemore amenable than radiowave to
synchronous ablations using multiple probes to obtain larger
coagulation volumes in shorter time.8
The procedure may be performed with sedation and local
anesthesia in outsetting patients. Pain is lesser than for
radiofrequency ablation probably because microwave ablationFig. 3. Microwave ablation of a primitive renal tumor. Pre-procedural CT (a). The procedure
inside the lesions is well visible (arrows). CT performed 1 months after the procedure withdo not involve the ﬂow of current within the body of the
patient.
3. Clinical applications
Microwave ablation has been applied to liver,2,11,8,12 kidney,13,14
lung,15 adrenal glands,2 pancreas16 and bone.2
In our preliminary experience we treated 4 liver nodules (Fig. 2)
(3 metastases from colon carcinoma and 1 recurrence of HCC after
radiofrequency ablation), 2 renal carcinomas (Fig. 3), 1 coeliac
lymphnode from pancreatic carcinoma, 1 bone metastasis from
uterine carcinoma, 1 primitive tumor of the lung (Fig. 4) and 1
pelvic recurrence from rectal cancer (unpublished data). Complete
ablation was obtained in 8/10 lesions: in 2/10 patients partial
ablation of bone metastasis and pelvic recurrence obtained
considerable pain reduction. Mean volume ablated, calculated
using a dedicated software (Vitrea 2/software 3.8/Vital Images) was
10.5 cm3 (unpublished data).
Clinical indications are the same as those reported for other
ablation therapies, above all patients not candidates to surgery. In
particular percutaneous ablative therapy allow to destroy
neoplastic tissue while preserving healthy parenchyma; this is an
important advantage above all in patients with impaired hepatic,
renal or pulmonary function.17–21 Therapeutic purpose can be
curative or palliative; in this last case microwave ablation is aimed
to reduce symptoms, above all pain or recurrent bleeding.22
From a technical point of view microwave ablation is prefer-
able in the treatment of lesion larger than 4 cm, with a cystic
component or localized close to vessels larger than 3 mm;
moreover it can be the ﬁrst choice in case of recurrence after
other ablation techniques.
About primitive or metastatic liver tumors the most
frequent limitation of radiofrequency ablation is the difﬁcultywas performed with contrast-enhanced US (b-c) and C-arm cone-beam CT (d); antenna
calculation of ablation volume (e-f).
Fig. 4. Microwave ablation of a primitive lung tumor. Pre-procedural TC (a); pulmonary artery branches close to the lesion are well visible (arrow). The procedure was performed
under CT-ﬂuoroscopy guide (b) using 2 antennas (arrows); performed after the procedure (c) shows ablated area with air inclusions and integrity of vessels inside the tumor
(arrow).
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cially portal branches and hepatic veins). An ‘‘ablate and
resect’’ study published by Simon et al.8 shows a uniform
tumor kill extending close to the vessels; moreover large
blood vessels (>3 mm) in the resection specimens did not
create typical ablation zone distortion because of the minimal
heat sink effect observed.2
In another study about renal tumors,14 histochemical exami-
nations revealed no cell death beyond the ablation area: this is
particularly important in renal ablation to preserve healthy
parenchyma and above all vascular and caliceal structures.4. Evaluation of the results
After many ablative therapies a strict follow-up is mandatory
due to exclude microscopic foci of viable neoplastic cells unde-
tectable with imaging methods.23 However, in the study by Clark
et al.14 histopathologic examination, after microwave ablation,
showed no viable cell inside the ablation zone.
As reported in literature, to evaluate cellular death after thermal
ablation, tissue must be analyzed with the vital histochemical
NADH stain for the mitochondrial enzyme nicotinamide adenine
dinucleotide (NADH) diaphorase.23
Hematoxylin–eosin (H–E) staining shows amarked thermal-like
effect with maximal intensity close to the antenna site and
a surrounding area of hyperemia; nevertheless some areas dis-
played only a subtle loss of nuclear chromatin detail with minimalTable 1
Author Year Organ No of patients
Volume of nodules
Approach
Iannitti DA
200712
Liver (primitive and
metastases)
87 mean 3.6 cm
(range 0.5–9 cm)
45%: open, 7%:
laparoscopy, 45%:
percutaneous (US/CT-
ﬂuoroscopy)
Wolf FJ 200815 Lung (primitive and
metastases)
50 3.5 1.6 percutaneous
(CT-guided)
Martin RC
200733
Liver (primitive and
metastases)
20 pt mean 3 cm
(range 1.5–4.5)
open or laparoscopic
Liang P 200813 Kidney (primitive) 12 mean 2.5
(range 1.3–3.8)
percutaneous
(US-guided)cell membrane destruction. NADH staining is able to discern areas
with cellular viability and those with uniform cellular death.8,14
As reported for RF ablation, at imaging follow-up, lack of
contrast enhancement on CT, MR or CEUS, indicates the absence of
viable tumor.21,24–27,13 Evaluation of contrast enhancement is easier
in hypervascular tumor such as hepatocarcinoma or renal carci-
noma. The detection of residual viable tissue in hypovascular
lesions can be aid byMR or PET. MR Imagingmay have an edge over
CT in the detection of local regrowths due to the high sensitivity of
T2-weighted sequence; the role of diffusion-weighted images is
under investigation.28,29
5. Literature review
Several pre-clinical studies have been published to assess safety
of microwave energy application, to evaluate morphology, size and
histologic features of ablation area in different tissues and to
analyze effects of different antenna patterns.7,4,5,30–32 Other phase I
clinical trials14,8,11 have been performed to conﬁrm effectiveness of
microwave ablation in patients undergoing tumor resection (ablate
and resect intraoperative trials). Clark et al.14 in a trial including 10
renal tumors, ablated with laparoscopic approach using 60W for
10 min and then resected, reported amean size of the ablated tissue
with a single probe of 4.12.72.2 cm (total rectilinear volume,
27 cm3; prolate spheroid volume, 15 cm3); with a three-probe
array, the mean size of the ablative lesion was 5.74.7 3.8 cm
(total rectilinear volume, 105 cm3; prolate spheroid volume,
56 cm3). Regarding hepatic ablation, Simon et al.8 reported a seriesAblation Results Follow-up
clustered or single
antenna, 45 W,
10 min
- single antenna ablation
volumes: 10.0 ml
(range 7.8–14.0 ml)
- clustered antennae ablation
volumes: 50.5 ml
(range 21.1–146.5 ml)
- mortality: 0%
- local complications rate: 9.1%
19 months, local
recurrence rate:
2.7%
straight or
multitine
deployable ring,
1–4 antennae, 45–
60W, 5–10 min
- Initial technical success: 95%
- Pneumothorax: 39%
- Hemoptysis: 6.6%
- Skin burns: 36%
10 months, residual
disease: 26%, local
recurrence rate:
22%, 1-year local
control rate: 67%
straight - Initial technical success: 100%
- related complications: 0%
19 months, local
recurrence: 1.5%
Cooled shaft
antenna, 50 W,
500 s
- Initial technical success: 100%
- related complications: 0%
11 months, local
recurrence: 0%
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intra-operative US-guide with a triple antenna; they obtained an
average ablation zone volume of 50.8 cm3 (range, 30.3–65.5 cm3);
gross and microscopic examinations of areas after microwave
ablation showed clear coagulation necrosis, even surrounding large
hepatic vessels (>3 mm in diameter); a marked thermal-like effect
was observed with maximal intensity close to the antenna sites;
NADH staining conﬁrmed the uniform absence of viable tumor in
the ablation zone.
In literature only few phase II studies appeared,12,13,15,33
including renal, lung and hepatic tumors (Table 1).6. Conclusion
Our preliminary results and those reported in literature support
the use of microwave ablation for the treatment of different type of
tumors. This technology can be applied in selected patient not
candidate to surgery, as an alternative to other ablative techniques.
Its results seem to be similar to RF ablation for lesions smaller than
3 cm; for tumors larger than 3 cm microwave ablation can be
conducted using multiple probe simultaneously. Microwave abla-
tion seems to be better for cystic tumors and for lesions close to
vessel larger than 3 mm. Further studies are necessary to conﬁrm
short- and long-term effectiveness of the methods and to compare
it with other ablative techniques, especially RF.Conﬂict of interest
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